Detection of spironolactone-associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES)

Drug Safety

Volumn 30, Issue 12, 2007, Pages 1143-1149

  Hauben, Manfred ^a,b,c,d   Reich, Lester ^a   Gerrits, Charles M ^e   Madigan, David ^f  

^a PFIZER INC   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d BRUNEL UNIVERSITY   (United Kingdom)

^e TAKEDA PHARMACEUTICALS   (United States)

^f RUTGERS UNIVERSITY   (United States)

Author keywords

ACE inhibitors, adverse reactions; Adverse drug reactions incidence; Hyperkalaemia, drug induced; Spironolactone, adverse reactions

Indexed keywords

BENAZEPRIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LISINOPRIL; PERINDOPRIL; QUINAPRIL; RAMIPRIL; SPIRONOLACTONE; TRANDOLAPRIL;

ALGORITHM; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HUMAN; HYPERKALEMIA; MORBIDITY; MORTALITY; PATIENT MONITORING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCORING SYSTEM;

EID: 36448936003     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730120-00006     Document Type: Article

References (16)

1. Wald NJ, Morris JK. Teleoanalysis: combining data from different types of study. BMJ 2003; 327: 616-8
2. Juurlink DM, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351 (6): 543-51
3. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-17
4. Zar JH. Biostatistical analysis. 4th rev. ed. Upper Saddle River (NJ): Prentice-Hall, 1998
5. DuMouchel W, Pregibon D. Empirical Bayes screening for multi-item associations. In: Proceedings of the ACM Conference on Knowledge Discovery and Data Mining 2001 Aug 26-29; San Francisco (CA): 67-76
6. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system (with discussion). Am Stat 1999; 53 (3): 177-202
7. Hauben M, Madigan D, Gerrits CM, et al. The role of data mining in pharmacovigilance. Expert Opin Drug Saf 2005; 4 (5): 929-48
8. Besancon JF, Lagarce L, Laine-Cessac P, et al. Biological survey in patients treated with the combination spironolactone and angiotensin converting enzyme inhibitor: a population-based analysis. Drug Saf 2006; 29 (10): 929
9. Raebel MA, McClure DL, Chan AK. Laboratory evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia? Ann Pharmacother 2007; 41 (2): 193-200
10. Hauben M, Reich L, Gerrits CM. Reports of hyperkalemia after publication of RALES: a pharmacovigilance study. Pharmacoepidemiol Drug Saf 2006; 15 (11): 775-83
11. Moore N, Hall G, Sturkenboom M, et al. Biases affecting the proportional reporting ratio (PRR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf 2003; 12 (4): 271-81
12. Strom BL. Potential for conflict of interest in the evaluation of suspected adverse drug reactions a counterpoint. JAMA 2004; 292 (21): 2643-6
13. Hochberg AM, Reisinger SJ, Pearson RK, et al. Using data mining to predict safety actions from FDA adverse event reporting system data. Drug Inf J 2007; 41: 633-43
14. Orre R, Bate A, Noren GN, et al. A Bayesian recurrent neural network for unsupervised pattern recognition in large incomplete data sets. Int J Neural Syst 2005; 15 (3): 207-22
15. Department of Health and Human Services. Food and Drug Administration 21 CFR Parts 310, 314, and 600 postmarketing expedited adverse experience reporting for human drug and licensed biological products. Increased Frequency Reports Federal Register 1997 Jun 25; 62 (122): 34166-8
16. Bate A, Edwards IR. Data mining in spontaneous reports. Basic Clin Pharmacol Toxicol 2006; 98 (3): 324-30